Comment from Cochran Meghan

I am writing to oppose the proposal to exclude semaglutide, tirzepatide, and liraglutide from the 503B Bulk Drug Substances List. Restricting 503B outsourcing facilities from compounding these medications will create a public health problem because these medications have drastically reduced the incidence of insulin resistance, diabetes, and heart disease, leading causes of death, discomfort, and cascading negative health outcomes. Brand-name versions of these drugs are often unavailable for millions of Americans. If patients cannot access the drug, they cannot get benefits of treatment. Blocking 503B facilities prioritizes pharmaceutical companies over the health of citizens. I urge adding these substances to the 503B Bulk List to ensure continued, safe, and affordable access to these life-saving treatments. For many Americans, our health options are limited. We have choice in theory, but often not in practice. Access to these medications is a significant factor in quality of life.